Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulon – page 26

1 537 clinical trials in Toulon, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulon at a glance
1 537
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 537 trials in Toulon

Open in trial search

Pyruvate dehydrogenase complex deficiency

Recruiting

Study of glycerol phenylbutyrate (oral liquid) for treatment of fatigue in patients with pyruvate dehydrogenase deficiency

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Glycerol Phenylbutyrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Septic shock

Recruiting

Study on Adding Vasopressin to Treat Patients with Septic Shock

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Assistance Publique Hopitaux De Marseille

Neoplasm

Recruiting

Study of ALE.P02 for Adults with Advanced or Metastatic Squamous Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALE.P02
  • Sponsor:Alentis Therapeutics AG

Non-small cell lung cancer

Recruiting

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Institut Gustave Roussy

Adult T-cell lymphoma/leukaemia refractory

Recruiting

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Neoplasm malignant

Recruiting

Study on the Safety and Effects of BMS-986507 with Pembrolizumab and Osimertinib Mesylate in Adults with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib mesylate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Dry age-related macular degeneration

Recruiting

Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Na-GAL-IPA
  • Sponsor:Galimedix Therapeutics Inc.

Granulomatosis with polyangiitis

Recruiting

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Lupus nephritis

Recruiting

Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Toulon

What the registry says about research in the country

01 Oncology - Lung Cancer Research

Extensive clinical trials focusing on non-small cell lung cancer treatments, including innovative combination therapies and immunotherapy approaches. Multiple studies evaluating novel drug combinations to improve patient outcomes.

  • Advanced NSCLC Treatments
  • Immunotherapy Combinations
  • Post-Surgery Therapies

Research spans various disease stages and includes both early-stage and metastatic cancer treatments.

02 Hematology & Blood Disorders

Studies investigating treatments for chronic lymphocytic leukemia and blood-related conditions. Research includes evaluation of novel drug combinations and targeted therapies.

  • Leukemia Treatments
  • Blood Cancer Therapies
  • Lymphoma Management

Focus on improving treatment outcomes for previously untreated patients with coexisting conditions.

03 Cardiovascular Research

Investigations into stroke prevention and treatment of thrombotic conditions. Studies evaluating new anticoagulants and therapeutic approaches for various cardiovascular conditions.

  • Thrombosis Management
  • Heart Failure Treatments
  • Stroke Prevention Strategies

Clinical trials examining innovative treatments for atrial fibrillation and deep vein thrombosis.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.